To appraise the clinical and cost effectiveness of Lenalidomide within its marketing authorisation for previously treated follicular lymphoma and marginal zone lymphoma.
 
Status In progress
Process STA 2018
ID number 1374

Provisional Schedule

Expected publication 01 April 2020

Project Team

Project lead Louise Jafferally

Email enquiries

Evidence Review Group / Assessment Group Kleijnen Systematic Reviews Ltd

Consultees

Companies sponsors Celgene (lenalidomide)
Others Department for Health and Social Care
  NHS England
  NHS Southampton CCG
  Welsh Government
Patient carer groups Lymphoma Action
  Leukemia Care
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists

Commentators

Comparator companies Bristol-Myers Squibb (etoposide) (confidentiality agreement signed)
  Janssen-Cilag (doxorubicin) (confidentiality agreement signed)
  Merck Sharpe & Dohme (interferon alfa) (confidentiality agreement signed)
  Accord Healthcare (bendamustine, doxorubicin, etoposide, mitoxantrone, prednisolone) (confidentiality agreement not signed)
  Allergan (prednisolone) (confidentiality agreement not signed)
  Aspen (chlorambucil) (confidentiality agreement not signed)
  Bausch & Lomb UK (prednisolone) (confidentiality agreement not signed)
  Baxter Healthcare (cyclophosphamide, mitoxantrone) (confidentiality agreement not signed)
  Bayer (prednisolone) (confidentiality agreement not signed)
  Concordia International (prednisolone) (confidentiality agreement not signed)
  Dr. Reddy’s Laboratories (bendamustine) (confidentiality agreement not signed)
  Hospira UK (mitoxantrone, vincristine) (confidentiality agreement not signed)
  Intrapharm Laboratories (prednisolone) (confidentiality agreement not signed)
  Logixx Pharma Solutions (prednisolone) (confidentiality agreement not signed)
  Medac GmbH (bendamustine, doxorubicin, etoposide) (confidentiality agreement not signed)
  Napp Pharmaceuticals (rituximab, bendamustine) (confidentiality agreement not signed)
  Pfizer (doxorubicin) (confidentiality agreement not signed)
  Roche Products (interferon alfa, rituximab) (confidentiality agreement not signed)
  Sandoz (rituximab, cyclophosphamide) (confidentiality agreement not signed)
  Seacross Pharmaceuticals (doxorubicin) (confidentiality agreement not signed)
  Teva UK (doxorubicin) (confidentiality agreement not signed)
  Wockhardt UK (prednisolone) (confidentiality agreement not signed)
  Zentiva (bendamustine, prednisolone) (confidentiality agreement not signed)
General commentators British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
17 May 2019 Invitation to participate
13 February 2018 In progress, Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance